CN1634515A - Qinglianghou drop pill for treating common cold and throat disease and its preparation method - Google Patents
Qinglianghou drop pill for treating common cold and throat disease and its preparation method Download PDFInfo
- Publication number
- CN1634515A CN1634515A CN 200410097168 CN200410097168A CN1634515A CN 1634515 A CN1634515 A CN 1634515A CN 200410097168 CN200410097168 CN 200410097168 CN 200410097168 A CN200410097168 A CN 200410097168A CN 1634515 A CN1634515 A CN 1634515A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- drop pill
- principal agent
- qinglianghou
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicinal oral preparation, i.e., a throat refrigerating drop pill for treating cold and throat pains. The medicine is prepared through the conventional drop pill preparing processes, which has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, less toxic and side effects, higher medicinal content, smaller amount of administration, accurate administration dosage, easy administration, low price, and facilitated carrying.
Description
Technical field
The present invention relates to a kind of dispelling wind and heat pathogens that has, the clearing throat effect; Be used for the treatment of anemopyretic cold, the oral drop pills of diseases such as laryngopharynx swelling and pain---the Qinglianghou drop pill pharmaceutical composition, particularly based on the refrigerant lozenge of Chinese traditional patent formulation, change a social system a kind of drug composition oral dropping pill formulation that forms through dosage form.
Background technology
According to ministry standard WS
3The refrigerant lozenge that prescription that provides among-the B-2429-97 and method for making are prepared from, a kind of have dispelling wind and heat pathogens, a clearing throat effect; Be used for the treatment of anemopyretic cold, the oral tablet class preparation of diseases such as laryngopharynx swelling and pain, through clinical verification for many years, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.
Below be drug standard WS
3The prescription of the refrigerant lozenge that provides among-the B-2429-97 and method for making:
Prescription: Oleum Eucalypti 0.5ml, Mentholum 1.25g, Fructus Citri oil 0.5ml, Oleum menthae 0.75ml;
Method for making: above four flavors, with citric acid 0.75g, use an amount of dissolve with ethanol, add adjuvant, mixing is made granule, drying; Oleum Eucalypti, Fructus Citri oil, Oleum menthae mixing add Mentholum and make dissolving, with above-mentioned granule mixing, be pressed into 1000, promptly.Be explained as follows for this tablet in the appended refrigerant lozenge description:
Nomenclature of drug: refrigerant lozenge;
Main component: Oleum Eucalypti, Oleum menthae, Mentholum, Fructus Citri oil;
Character: this product is azury; Have Herba Menthae fragrance, the flavor sweet;
Function cures mainly: dispelling wind and heat pathogens, and clearing throat is used for anemopyretic cold, laryngopharynx swelling and pain;
Usage and dosage: buccal, one time 1, every 0.5～1 hour buccal once.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.
In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention is to replenish existing have dispelling wind and heat pathogens, clearing throat effect, be used for the treatment of anemopyretic cold, the deficiency of the oral drug preparation of symptoms such as laryngopharynx swelling and pain provides a kind of bioavailability height, release fast, quick produce effects, toxic and side effects is littler, and medicament contg height, taking dose is little, and taking dose is accurate, taking convenience, cheap, and be convenient to the drug composition oral preparation Qinglianghou drop pill of going out to carry.
Qinglianghou drop pill involved in the present invention determines that through a large amount of experiment sievings based on the preparation process of the refrigerant lozenge of Chinese traditional patent formulation, process is adjusted the part preparation process, and cooperates drop pill preparation technology to be prepared from.Be prepared by the following technical solutions, can obtain Qinglianghou drop pill involved in the present invention:
[preparation method]
1. Oleum Eucalypti 0.5ml, Mentholum 1.25g, Fructus Citri oil 0.5ml, Oleum menthae 0.75ml; More than four flavors, Oleum Eucalypti, Fructus Citri oil, Oleum menthae mixing add Mentholum and make dissolving, promptly get principal agent.
2. substrate---one or more the mixture in pharmaceutically suitable carrier such as Polyethylene Glycol (2000,4000,6000,8000,9300,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing principal agent and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing principal agent and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively is in above the 2nd step during desired state of temperature, and under the temperature conditions close with the water dropper temperature, insulation places in the water dropper jar of drop pill machine, splashes in the condensing agent by water dropper;
Condensing agent can be any one of liquid paraffin, methyl-silicone oil, vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
Beneficial effect
According to ministry standard WS
3The refrigerant lozenge that prescription that provides among-the B-2429-97 and extraction process are prepared from is a kind of dispelling wind and heat pathogens that has, the clearing throat effect; Be used for the treatment of anemopyretic cold, the tablet class preparation of symptoms such as laryngopharynx swelling and pain, through clinical verification for many years, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.
In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Qinglianghou drop pill involved in the present invention is compared with refrigerant lozenge, has following beneficial effect:
1. Qinglianghou drop pill involved in the present invention; utilize surfactant etc. to be substrate; make solid dispersion with principal agent; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases; and substrate has wetting action to medicine, can make that medicine is rapidly molten to loose into microgranule or solution, thereby makes the dissolving of medicine and absorb and accelerate.Thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
Compare with the administering mode of traditional oral formulations, exist essential distinction.With the drop pill of solid dispersion technology preparation, can adopt oral, can also sublingual administration, effective ingredient is fully contacted with mucomembranous surface, by the mucomembranous epithelial cell absorption, directly enter blood circulation.Owing to directly enter blood circulation without gastrointestinal tract and liver, avoided first pass effect effectively, also avoided gastrointestinal irritation, thereby it is rapid to have an onset, bioavailability height, characteristics such as side effect is little, and medication is convenient.
2. Qinglianghou drop pill involved in the present invention contacts promptly with saliva and to dissolve rapidly, and is absorbed by oral mucosa, and is not only rapid-action, and the influence of not taken food, and promptly all can containing take after meal ante cibum, and local application's onset is faster.
3. Qinglianghou drop pill involved in the present invention mixes the principal agent that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
In sum, make Qinglianghou drop pill involved in the present invention have the advantage of triple effect (quick-acting, efficient, long-acting), three little (taking dose is little, toxicity is little, side effect little), five convenience (convenient for production, store convenience, convenient transportation, easy to carry, easy to use).
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of Qinglianghou drop pill of the present invention.
First group: the test of single-matrix
1. the ratio that provides according to [preparation method] 1 takes by weighing the raw material of Chinese medicine of some, and is prepared into satisfactory principal agent, and is standby;
2. substrate: Polyethylene Glycol
(2000,4000,6000,8000,9300,10000,20000), pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
4. be prepared according to the process of [preparation method] 4～7 again, promptly can make the Qinglianghou drop pill of various different sizes.
[result of the test]
Test 1: for observe principal agent and different substrates when 1: 1 the proportioning prepared Qinglianghou drop pill in qualitative difference, according to 1: 1 ratio, with principal agent respectively with Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 1.
Test 2: for observe principal agent and different substrates when 1: 3 the proportioning prepared Qinglianghou drop pill in qualitative difference, according to 1: 3 ratio, with principal agent respectively with Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 2.
Test 3: for observe principal agent and different substrates when 1: 9 the proportioning prepared Qinglianghou drop pill in qualitative difference, according to 1: 9 ratio, with principal agent respectively with Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. the ratio that provides according to [preparation method] 1 takes by weighing the raw material of Chinese medicine of some, and is prepared into satisfactory principal agent, and is standby;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstaeh Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. (with g or kg is unit to proportioning, by weight)
3.1 the ratio of composite interstitial substance---polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10,
3.2 mixing principal agent: mixed-matrix weight and=1: 1～1: 9.
4. be prepared according to the process of [preparation method] 4～7 again, promptly can make the Qinglianghou drop pill of various different sizes.
[result of the test]
Test 4: for observe principal agent and mixed-matrix when 1: 1 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 4.
Test 5: for observe principal agent and mixed-matrix when 1: 3 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 5.
Test 6: for observe principal agent and mixed-matrix when 1: 9 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 6.
Test 7: for observe principal agent and mixed-matrix when 1: 1 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 7.
Test 8: for observe principal agent and mixed-matrix when 1: 3 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 8.
Test 9: for observe principal agent and mixed-matrix when 1: 9 the proportioning prepared Qinglianghou drop pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 9.
Test 10: in order to observe Qinglianghou drop pill that principal agent and mixed-matrix make when 1: 1 the proportioning in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 10.
Test 11: in order to observe Qinglianghou drop pill that principal agent and mixed-matrix make when 1: 3 the proportioning in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 11.
Test 12: in order to observe Qinglianghou drop pill that principal agent and mixed-matrix make when 1: 9 the proportioning in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 12.
The group practices of table 1 principal agent and single-matrix
(principal agent: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ????50.0 | ????70 | ????＜30 | ????＞10 | + |
| Polyethylene Glycol 4000 | ????50.0 | ????76 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 6000 | ????50.0 | ????82 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 8000 | ????50.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 9300 | ????50.0 | ????88 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 10000 | ????50.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 20000 | ????50.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Polyoxyethylene stearate 40 esters | ????50.0 | ????78 | ????＜30 | ????＞10 | ++ |
| Betacyclodextrin | ????50.0 | ????72 | ????＜30 | ????＞10 | + |
| Poloxamer | ????50.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Carboxymethyl starch sodium | ????50.0 | ????73 | ????＜30 | ????＞10 | + |
| Sodium lauryl sulphate | ????50.0 | ????68 | ????＞30 | ????＞10 | ++ |
| Stearic acid | ????50.0 | ????55 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????50.0 | ????54 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????50.0 | ????55 | ????＞30 | ????＞10 | +++ |
| Lac | ????50.0 | ????52 | ????＞30 | ????＞10 | +++ |
The group practices of table 2 principal agent and single-matrix
(principal agent: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ????25.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 4000 | ????25.0 | ????86 | ????＜30 | ????＜10 | ++ |
| Polyethylene Glycol 6000 | ????25.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 8000 | ????25.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 9300 | ????25.0 | ????94 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 10000 | ????25.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 20000 | ????25.0 | ????91 | ????＜30 | ????＜10 | ++ |
| Polyoxyethylene stearate 40 esters | ????25.0 | ????92 | ????＜30 | ????＜10 | ++ |
| Betacyclodextrin | ????25.0 | ????82 | ????＜30 | ????＞10 | ++ |
| Poloxamer | ????25.0 | ????89 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium | ????25.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Sodium lauryl sulphate | ????25.0 | ????77 | ????＜30 | ????＞10 | ++ |
| Stearic acid | ????25.0 | ????73 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????25.0 | ????72 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????25.0 | ????71 | ????＞30 | ????＞10 | +++ |
| Lac | ????25.0 | ????72 | ????＞30 | ????＞10 | +++ |
The group practices of table 3 principal agent and single-matrix
(principal agent: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ????10.0 | ????83 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 4000 | ????10.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 6000 | ????10.0 | ????94 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 8000 | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 9300 | ????10.0 | ????89 | ????＜30 | ????＞10 | +++ |
| Polyethylene Glycol 10000 | ????10.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 20000 | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyoxyethylene stearate 40 esters | ????10.0 | ????93 | ????＜30 | ????＜10 | ++ |
| Betacyclodextrin | ????10.0 | ????88 | ????＜30 | ????＜10 | ++ |
| Poloxamer | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium | ????10.0 | ????86 | ????＜30 | ????＜10 | +++ |
| Sodium lauryl sulphate | ????10.0 | ????83 | ????＜30 | ????＞10 | +++ |
| Stearic acid | ????10.0 | ????76 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????10.0 | ????77 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????10.0 | ????74 | ????＞30 | ????＞10 | +++ |
| Lac | ????10.0 | ????73 | ????＞30 | ????＞10 | +++ |
The group practices of table 4 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????50 | ????85 | ????＜30 | ????＜10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????50 | ????86 | ????＜30 | ????＜10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????50 | ????81 | ????＜30 | ????＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????50 | ????78 | ????＜30 | ????＞10 | + |
The group practices of table 5 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????25 | ????92 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????25 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????25 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????25 | ????86 | ????＜30 | ????＞10 | ++ |
The group practices of table 6 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????10 | ????92 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????10 | ????92 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????10 | ????90 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????10 | ????84 | ????＜30 | ????＞10 | +++ |
The group practices of table 7 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????50 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????50 | ????94 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????50 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????50 | ????83 | ????＜30 | ????＞10 | ++ |
The group practices of table 8 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????25 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????25 | ????95 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????25 | ????92 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????25 | ????89 | ????＜30 | ????＜10 | ++ |
The group practices of table 9 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????10 | ????95 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????10 | ????94 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????10 | ????91 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????10 | ????88 | ????＜30 | ????＜10 | +++ |
The group practices of table 10 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????50 | ????91 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????50 | ????91 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????50 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????50 | ????82 | ????＜30 | ????＞10 | +++ |
The group practices of table 11 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????25 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????25 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????25 | ????90 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????25 | ????87 | ????＜30 | ????＜10 | +++ |
The group practices of table 12 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????10 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????10 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????10 | ????91 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????10 | ????90 | ????＜30 | ????＜10 | +++ |
1. can be seen by the result in the table: when the ratio of principal agent and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of principal agent and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of principal agent and substrate is 1: 9, though the rounding rate, the ball method of double differences is different and index such as hardness has raising, and is not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (5)
1. one kind has dispelling wind and heat pathogens, the clearing throat effect; Be used for the treatment of anemopyretic cold, the pharmaceutical composition Qinglianghou drop pill of diseases such as laryngopharynx swelling and pain, with Oleum Eucalypti, Mentholum, Fructus Citri oil, Oleum menthae is raw material of Chinese medicine, after preparing the principal agent that contains the said medicine active component, further be prepared from a certain proportion of pharmaceutically suitable carrier, wherein:
1.1. Oleum Eucalypti 0.5ml, Mentholum 1.25g, Fructus Citri oil 0.5ml, Oleum menthae 0.75ml; More than four flavors, Oleum Eucalypti, Fructus Citri oil, Oleum menthae mixing add Mentholum and make dissolving, promptly get principal agent.
1.2. substrate---Polyethylene Glycol
(2000,4000,6000,8000,9300,10000,20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
1.3. proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9.
2. Qinglianghou drop pill as claimed in claim 1 is characterized in that: described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or Polyethylene Glycol and poloxamer or Polyethylene Glycol and carboxymethyl starch sodium or Polyethylene Glycol and betacyclodextrin; With g or kg is unit, and by weight, its mixed proportion is polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10.
3. any Qinglianghou drop pill as claimed in claim 1 or 2 is characterized in that: the mixed proportion of described principal agent and substrate is 1: 1～1: 5.
4. the preparation method of a Qinglianghou drop pill is characterized in that being made of following process:
4.1. Oleum Eucalypti 0.5ml, Mentholum 1.25g, Fructus Citri oil 0.5ml, Oleum menthae 0.75ml; More than four flavors, Oleum Eucalypti, Fructus Citri oil, Oleum menthae mixing add Mentholum and make dissolving, promptly get principal agent.Standby;
4.2. substrate---Polyethylene Glycol
(1000,2000,4000,6000,8000,9300,10000,20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
4.3. proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
4.4., accurately take by weighing principal agent and substrate according to the given ratio of prescription, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing principal agent and substrate and/or emulsion and/or suspension;
4.5. adopt homemade or general drop pill machine, and adjust the temperature control system of drop pill machine, make the water dropper temperature heating of drop pill machine and remain on 50 ℃～90 ℃, the temperature cooling of condensing agent also remains on-5 ℃～40 ℃;
4.6. treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively is in above the 2nd step during desired state of temperature, under the temperature conditions close, be incubated with the water dropper temperature, place in the water dropper jar of drop pill machine, splash in the condensing agent by water dropper and shrink shaping promptly.
5. as the preparation method of Qinglianghou drop pill as described in the claim 5, it is characterized in that: method 5.6 described condensing agents are methyl-silicone oils or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100971685A CN1322853C (en) | 2004-12-13 | 2004-12-13 | Qinglianghou drop pill for treating common cold and throat disease and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100971685A CN1322853C (en) | 2004-12-13 | 2004-12-13 | Qinglianghou drop pill for treating common cold and throat disease and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634515A true CN1634515A (en) | 2005-07-06 |
| CN1322853C CN1322853C (en) | 2007-06-27 |
Family
ID=34847927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100971685A Expired - Fee Related CN1322853C (en) | 2004-12-13 | 2004-12-13 | Qinglianghou drop pill for treating common cold and throat disease and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1322853C (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481866A (en) * | 2003-07-22 | 2004-03-17 | 许猛太 | Healthcare food with function of wetting one's whistle |
-
2004
- 2004-12-13 CN CNB2004100971685A patent/CN1322853C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1322853C (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1301098C (en) | Hairy holly root drip pill and its preparation method | |
| CN1686342A (en) | Herminium drip pill and its preparation method | |
| CN1686389A (en) | Danhong drip pill prepared from salvia root and carthamus and its preparation method | |
| CN1297254C (en) | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof | |
| CN1634509A (en) | Yitongshu drop pill for treating pain and its preparation method | |
| CN1287771C (en) | Almond cough-relieving drop pills and preparation method thereof | |
| CN1634452A (en) | Yin-nourishing lung-heat clearing drop pills | |
| CN1679673A (en) | Isatis root drops and preparation thereof | |
| CN1679675A (en) | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof | |
| CN1301094C (en) | Throat pain relieving anti-inflammation drop pills for treating oral disease and preparation method thereof | |
| CN1679669A (en) | Polygala dropping balls and preparation thereof | |
| CN1686452A (en) | Two kinds of oral drip pills for treating tracheitis and its preparation method | |
| CN1301107C (en) | Xiyanping drop pills of possessing function of clearing away heat and toxic materia and preparation method | |
| CN1307978C (en) | Drop pill for diminishing inflammation in four seasons and its preparation method | |
| CN1634515A (en) | Qinglianghou drop pill for treating common cold and throat disease and its preparation method | |
| CN1301095C (en) | 'Yinchai' drop pills for treating cold, fever and cough and preparation method | |
| CN1634487A (en) | Dripping pills for treating high blood fat and its preparing method | |
| CN1634145A (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN1679671A (en) | Compound berberine dropping ball and preparation thereof | |
| CN1634490A (en) | Drop pills for treating throat diseases and preparation method thereof | |
| CN1679672A (en) | Rabdosia rubescens drops and preparation thereof | |
| CN1682818A (en) | Fleabane and earthworm dripping pill and its preparing method | |
| CN1709420A (en) | Motherwort dropping pill and its preparing method | |
| CN1709468A (en) | Pulmonary-toxin-clearing dropping pill using hop extract as raw material, and its preparing method | |
| CN1698819A (en) | Schizandrol dripping pills for decreasing aminopherase and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070627 Termination date: 20100113 |